Pfizer Announces New Strategic Partnerships with ICON and PAREXEL International Corporation
- Details
- Category: Pfizer
Pfizer Inc. announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011.
Major Subgroup Analysis Shows Bayer's Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes
- Details
- Category: Bayer
A pre-planned subgroup analysis of the ROCKET AF Phase III clinical study confirms that rivaroxaban is highly effective in the prevention of recurrent strokes in patients with atrial fibrillation (AF) who have experienced a prior stroke or transient ischemic attack (TIA).
Nycomed continues to outperform in emerging markets in first quarter 2011
- Details
- Category: Nycomed
Nycomed announced results for the first quarter of 2011, demonstrating continued outperformance in the key emerging economies which are driving growth in the global pharmaceuticals industry.
GSK forms partnership with three leading NGOs
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced further progress on its commitment to reinvest 20% of profits made in the Least Developed Countries (LDCs) back into projects that strengthen the healthcare infrastructure in those countries.
AstraZeneca signs agreement in Japan with Daiichi Sankyo to co-promote denosumab
- Details
- Category: AstraZeneca
AstraZeneca announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis.
Lilly and Investor Group Form New Critical Care Company BioCritica
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company.
Sanofi's Commitment to Research and Identify Treatments for Cancer Patients
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced that data from eight compounds in the company's robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.
More Pharma News ...
- SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
- Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business
- Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO
- Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc.
- Pfizer To Present New Research From Fifteen Compounds
- Patrick Dempsey Teams up With Breakaway from Cancer(R)
- New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer